New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

LB Pharmaceuticals Inc (LBRX) vs Nuvation Bio Inc. (NUVB)

LB Pharmaceuticals Inc and Nuvation Bio Inc. are both Biotechnology companies. Nuvation Bio Inc. is the larger, with a market value of $1.4B against $1.3B — 1.1× the size. LB Pharmaceuticals Inc has the higher net margin (0.00% vs −67.4%) and the lower return on invested capital (−686.2% vs 0.00%). Across the 13 metrics below, LB Pharmaceuticals Inc leads on 8 and Nuvation Bio Inc. on 5.

Valuation

Metric LBRX NUVB Biotechnology median
P/E n/m n/m 8.26
P/S n/m 6.65 9.20
P/B 3.17 5.88 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA n/m n/m 0.67
EV/Sales n/m 4.77 9.05
Earnings yield (11.54%) (10.35%) (34.24%)
Free cash flow yield (10.86%) (8.07%) (24.77%)

Profitability

Metric LBRX NUVB Biotechnology median
Gross margin — 85.79% 70.18%
Operating margin 0.00% (61.17%) 0.00%
Net margin 0.00% (67.38%) 0.00%
Free cash flow margin 0.00% (53.62%) 0.00%
Return on equity (38.80%) (49.09%) (51.58%)
Return on assets (36.48%) (19.70%) (45.91%)
Return on invested capital (686.18%) 0.00% 0.00%

Growth

Metric LBRX NUVB Biotechnology median
Revenue growth (TTM) — 654.19% 7.20%
EPS growth (last fiscal year) 98.22% 71.56% 29.04%
Revenue growth, 5-year CAGR — — 9.48%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric LBRX NUVB Biotechnology median
Debt to equity 0.00 1.25 0.00
Current ratio 14.78 7.45 4.83
Net debt to EBITDA 9.90 2.26 1.01

Dividend

Metric LBRX NUVB Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric LBRX NUVB Biotechnology median
Market cap 1.30b 1.43b 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack